Supernus Pharmaceuticals Statistics

Total Valuation

LON:0LB2 has a market cap or net worth of GBP 1.53 billion. The enterprise value is 1.21 billion.

Market Cap	1.53B
Enterprise Value	1.21B

Important Dates

The next estimated earnings date is Tuesday, August 5, 2025.

Earnings Date	Aug 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	62.62M
Shares Outstanding	n/a
Shares Change (YoY)	+2.52%
Shares Change (QoQ)	-1.06%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	55.11M

Valuation Ratios

The trailing PE ratio is 31.93 and the forward PE ratio is 18.21.

PE Ratio	31.93
Forward PE	18.21
PS Ratio	2.96
PB Ratio	1.92
P/TBV Ratio	4.80
P/FCF Ratio	12.10
P/OCF Ratio	12.04
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.74, with an EV/FCF ratio of 9.59.

EV / Earnings	25.29
EV / Sales	2.46
EV / EBITDA	10.74
EV / EBIT	28.05
EV / FCF	9.59

Financial Position

The company has a current ratio of 2.44, with a Debt / Equity ratio of 0.03.

Current Ratio	2.44
Quick Ratio	2.16
Debt / Equity	0.03
Debt / EBITDA	0.21
Debt / FCF	0.20
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 6.32% and return on invested capital (ROIC) is 3.60%.

Return on Equity (ROE)	6.32%
Return on Assets (ROA)	2.76%
Return on Invested Capital (ROIC)	3.60%
Return on Capital Employed (ROCE)	5.50%
Revenue Per Employee	767,096
Profits Per Employee	71,099
Employee Count	674
Asset Turnover	0.50
Inventory Turnover	1.24

Taxes

In the past 12 months, LON:0LB2 has paid 23.13 million in taxes.

Income Tax	23.13M
Effective Tax Rate	32.55%

Stock Price Statistics

The stock price has increased by +25.19% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+25.19%
50-Day Moving Average	32.17
200-Day Moving Average	33.41
Relative Strength Index (RSI)	55.40
Average Volume (20 Days)	36

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.50

Income Statement

In the last 12 months, LON:0LB2 had revenue of GBP 517.02 million and earned 47.92 million in profits. Earnings per share was 0.86.

Revenue	517.02M
Gross Profit	457.15M
Operating Income	45.36M
Pretax Income	71.05M
Net Income	47.92M
EBITDA	107.32M
EBIT	45.36M
Earnings Per Share (EPS)	0.86

Full Income Statement

Balance Sheet

The company has 358.81 million in cash and 25.00 million in debt, giving a net cash position of 333.81 million.

Cash & Cash Equivalents	358.81M
Total Debt	25.00M
Net Cash	333.81M
Net Cash Per Share	n/a
Equity (Book Value)	797.76M
Book Value Per Share	14.25
Working Capital	314.09M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 127.05 million and capital expenditures -622,288, giving a free cash flow of 126.43 million.

Operating Cash Flow	127.05M
Capital Expenditures	-622,288
Free Cash Flow	126.43M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 88.42%, with operating and profit margins of 8.77% and 9.27%.

Gross Margin	88.42%
Operating Margin	8.77%
Pretax Margin	13.74%
Profit Margin	9.27%
EBITDA Margin	20.76%
EBIT Margin	8.77%
FCF Margin	24.45%

Dividends & Yields

LON:0LB2 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.52%
Shareholder Yield	n/a
Earnings Yield	3.13%
FCF Yield	8.26%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0LB2 has an Altman Z-Score of 4.98 and a Piotroski F-Score of 7.

Altman Z-Score	4.98
Piotroski F-Score	7